(S (NP (NNP SARS) (HYPH -) (NNP CoV) (HYPH -) (NNP 2)) (VP (VBZ is) (NP (NP (DT a) (JJ severe) (JJ respiratory) (NN infection)) (SBAR (WHNP (WDT that)) (S (VP (VBZ infects) (NP (NNS humans))))))) (. .))
(S (NP (PRP$ Its) (NN outburst)) (VP (VBN entitled) (NP (PRP it)) (PP (IN as) (NP (DT a) (NN pandemic) (NN emergence)))) (. .))
(S (S (VP (TO To) (VP (VB get) (NP (DT a) (NN grip)) (PP (IN on) (NP (DT this)))))) (, ,) (NP (NN outbreak) (JJ specific) (NML (JJ preventive) (CC and) (JJ therapeutic)) (NNS interventions)) (VP (VBP are) (ADVP (RB urgently)) (VP (VBN needed))) (. .))
(S (NP (PRP It)) (VP (MD must) (VP (VB be) (VP (VBN said) (SBAR (IN that) (S (, ,) (PP (IN until) (ADVP (RB now))) (, ,) (NP (EX there)) (VP (VBP are) (NP (NP (DT no) (VBG existing) (NNS vaccines)) (PP (IN for) (NP (NNS coronaviruses)))))))))) (. .))
(S (S (VP (TO To) (ADVP (RB promptly) (CC and) (RB rapidly)) (VP (VB respond) (PP (IN to) (NP (NN pandemic) (NNS events)))))) (, ,) (NP (NP (DT the) (NN application)) (PP (IN of) (NP (ADJP (FW in) (FW silico)) (NNS trials)))) (VP (MD can) (VP (VP (VB be) (VP (VBN used) (PP (IN for) (S (VP (VBG designing) (CC and) (VBG testing) (NP (NNS medicines)) (PP (IN against) (NP (NNP SARS) (HYPH -) (NNP CoV) (HYPH -) (NNP 2)))))))) (CC and) (VP (VB speed) (HYPH -) (PRT (RP up)) (NP (DT the) (NML (NN vaccine) (NN discovery)) (NN pipeline)) (, ,) (S (VP (VP (VBG predicting) (NP (DT any) (JJ therapeutic) (NN failure))) (CC and) (VP (VBG minimizing) (NP (JJ undesired) (NNS effects)))))))) (. .))
(S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBP present) (NP (NP (DT an) (ADJP (FW in) (FW silico)) (NN platform)) (SBAR (WHNP (WDT that)) (S (VP (VBD showed) (NP (S (VP (TO to) (VP (VB be) (PP (IN in) (NP (ADJP (RB very) (JJ good)) (NN agreement))) (PP (IN with) (NP (NP (DT the) (JJS latest) (NN literature)) (PP (IN in) (S (VP (VBG predicting) (NP (NP (NNP SARS)) (HYPH -) (NP (NNP CoV)) (HYPH -) (NP (CD 2) (NNS dynamics))))))))))) (CC and) (NP (VBN related) (JJ immune) (NN system)) (NP (NN host) (NN response)))))))) (. .))
(S (ADVP (RB Moreover)) (, ,) (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (S (VP (TO to) (VP (VB predict) (NP (NP (DT the) (NN outcome)) (PP (IN of) (NP (NP (CD one)) (PP (IN of) (NP (DT the) (JJS latest) (VBN suggested) (NN approach)))))) (S (VP (TO to) (VP (VB design) (NP (DT an) (JJ effective) (NN vaccine)))))))) (, ,) (PP (VBN based) (PP (IN on) (NP (JJ monoclonal) (NN antibody))))))) (. .))
(S (NP (NNP UISS)) (VP (VBZ is) (ADVP (RB then)) (ADJP (RB potentially) (JJ ready)) (S (VP (TO to) (VP (VB be) (VP (VBN used) (PP (IN as) (NP (DT an) (ADJP (FW in) (FW silico)) (NN trial) (NN platform))) (S (VP (TO to) (VP (VB predict) (NP (NP (DT the) (NN outcome)) (PP (IN of) (NP (NN vaccination) (NN strategy)))) (PP (IN against) (NP (NNP SARS) (HYPH -) (NNP CoV) (HYPH -) (NNP 2))))))))))) (. .))
